Is a
Patent attributes
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Bruce A. Andrien, Jr.0
Douglas L. Sheridan0
Paul P. Tamburini0
Yi Wang0
Date of Patent
October 31, 2017
0Patent Application Number
154926220
Date Filed
April 20, 2017
0Patent Citations Received
Patent Primary Examiner
Patent abstract
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
